Dexmethylphenidate hydrochloride is under clinical development by Cingulate and currently in Phase III for Attention Deficit Hyperactivity Disorder (ADHD). According to GlobalData, Phase III drugs for ...

Cingulate Inc. announced the completion of its final FDA-required food effect study for CTx-1301, a medication intended for the treatment of ADHD. The study showed no serious adverse events ...

Cingulate (CING) announced that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD.

Psychedelic compounds produce intense subjective experiences and have shown promise in the treatment of posttraumatic stress disorder (PTSD) and treatment-resistant depression, amongst other ...

Anger and irritability aren’t part of the criteria used to diagnose ADHD, but clinicians and researchers have identified them as common experiences among children and adults with the condition.

These include parts of the prefrontal cortex (important for decision-making and cognitive control), the hippocampus, the anterior cingulate cortex ... brain’s reward circuit in ways that ...